PMID- 9675316
OWN - NLM
STAT- MEDLINE
DCOM- 19980901
LR  - 20190702
IS  - 0027-5107 (Print)
IS  - 0027-5107 (Linking)
VI  - 402
IP  - 1-2
DP  - 1998 Jun 18
TI  - Effect of selected antimutagens on the genotoxicity of antitumor agents.
PG  - 289-98
AB  - Cyclophosphamide (CP), bleomycin (BL), doxorubicin (DOX) and cisplatin (CISP) are 
      potent antitumor drugs used worldwide against many forms of human cancer. As with 
      most such agents, there can be physiological side-effects and the possible 
      induction of mutations and other genotoxic effects in non-tumor cells. It is 
      common for patients to ingest a host of food supplements to diminish the 
      discomforting side-effects of therapy. Because these food supplements are often 
      also rich in antimutagens that could also affect the biological efficacy of the 
      antitumor drugs, we investigated if such antimutagenic agents were indeed 
      antimutagenic to these antitumor drugs. Using the Salmonella/microsome bioassay, 
      we tested CP, BL, DOX, and CP for mutagenicity in the presence and absence of the 
      antimutagens ascorbic acid (AA), chlorophyllin (CHL) and (+)-catechin (CAT). AA 
      was a very effective antimutagen against CISP and less effective against BL and 
      DOX. It was not antimutagenic to CP. CHL was effective as an antimutagen against 
      all four antitumor drugs, and CAT was a strong inhibitor of DOX mutagenicity, but 
      had little effect on BL, CP and CISP. These data now provide a basis for future 
      in vivo antitumor/antimutagen combination studies to determine if these 
      antimutagens function in a manner to reduce genetic effects without having 
      concomitant effects on intended antitumorogenicity of these therapeutic agents.
CI  - Copyright 1998 Elsevier Science B.V. All rights reserved.
FAU - Gentile, J M
AU  - Gentile JM
AD  - Biology Department, Hope College, Holland, MI 49423, USA.
FAU - Rahimi, S
AU  - Rahimi S
FAU - Zwiesler, J
AU  - Zwiesler J
FAU - Gentile, G J
AU  - Gentile GJ
FAU - Ferguson, L R
AU  - Ferguson LR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Netherlands
TA  - Mutat Res
JT  - Mutation research
JID - 0400763
RN  - 0 (Antimutagenic Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Mutagens)
SB  - IM
MH  - Antimutagenic Agents/*pharmacology
MH  - Antineoplastic Agents/*adverse effects
MH  - Mutagenicity Tests
MH  - Mutagens/*adverse effects
MH  - Salmonella typhimurium/genetics
EDAT- 1998/07/24 00:00
MHDA- 1998/07/24 00:01
CRDT- 1998/07/24 00:00
PHST- 1998/07/24 00:00 [pubmed]
PHST- 1998/07/24 00:01 [medline]
PHST- 1998/07/24 00:00 [entrez]
AID - S0027-5107(97)00308-4 [pii]
AID - 10.1016/s0027-5107(97)00308-4 [doi]
PST - ppublish
SO  - Mutat Res. 1998 Jun 18;402(1-2):289-98. doi: 10.1016/s0027-5107(97)00308-4.